Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoxsuprine is a small molecule vasodilator and beta-adrenergic agonist used to treat conditions caused by poor blood circulation, such as peripheral vascular disease (including arteriosclerosis obliterans, Buerger's disease), Raynaud's disease, and cerebrovascular insufficiency. It acts primarily by relaxing vascular and uterine smooth muscle through stimulation of beta-adrenergic receptors, leading to dilation of arteries—especially those supplying skeletal muscle—thereby improving blood flow. Isoxsuprine has also been used off-label for the prevention of premature labor and for menstrual pain. The drug was previously marketed under brand names such as Vasodilan but has been withdrawn from the U.S. market due to lack of evidence for efficacy in its approved indications[1][2][3][4][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoxsuprine.